#biopharmaceutical

Collection of biopharmaceutical news, found 130 news.

Aptorum Group announces further positive data for its ALS-4 small molecule Anti-virulence (Non-bactericidal) drug candidate for the treatment of infections caused by Staphylococcus aureus and on track

- Aptorum Group Limited (NASDAQ: APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of ...

Ferring’s Propess® is the first pharmacological treatment for cervical ripening to be approved in Japan for over 20 years

- Ferring Pharmaceuticals today announced that Propess® (dinoprostone) has been approved by the Minister of Health, ...

Takeda continues strategic divestitures with sale of select OTC and non-core assets to STADA for $660 million USD

- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an ...

Takeda agrees to divest select OTC and non-core assets to Acino for over $200 million USD

- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an ...

Hansoh Pharma and Atomwise launch strategic AI drug discovery collaboration for multiple therapeutic areas

- Hansoh Pharmaceutical Group Company Limited (“Hansoh Pharma”), a leading biopharmaceutical company in China, and ...

APEC strives to bolster health ethics to support SMEs, patients

APEC continues to bolster ethics in the healthcare sector in support of small and medium enterprises (SMEs) and ...

Aptorum Group has initiated IND-enabling studies for its ALS-4 small molecule candidate for the treatment of infections caused by staphylococcus aureus including MRSA

- Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of ...

Aptorum Group announces the development of microbiome drug candidate targeting obesity and repurposed drug candidates targeting neuroblastoma

- Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of ...

Takeda completes sale of Xiidra® to Novartis

- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its sale ...

Terns Pharmaceuticals appoints Ankang Li, Ph.D., J.D., CFA as Chief Financial Officer

- Terns Pharmaceuticals, Inc., a global biopharmaceutical company focused on discovering and developing innovative ...

Terns Pharmaceuticals announces exclusive licensing and collaboration agreement with GENFIT to develop and commercialize elafibranor in the Greater China region

- Terns Pharmaceuticals, Inc. today announced an exclusive licensing and collaboration agreement with GENFIT (GNFT), a ...

Aeneas Capital and Pyrinas target launch of US$120m fund to develop co-working laboratory ecosystems for life sciences start-ups in the United States

    • Aeneas Capital and Pyrinas, both affiliated companies to Aptorum Group Ltd (Nasdaq: APM), is ...

Takeda simplifies portfolio and accelerates deleveraging through two divestitures

- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into ...

Terns Pharmaceuticals to present at BioCentury’s 26th Annual Future Leaders in Biotech Industry Conference

- Terns Pharmaceuticals Inc., a global biopharmaceutical company focused on discovering and developing molecularly ...

Terns Pharmaceuticals announces the appointment of Erin Quirk, M.D., as Chief Medical Officer

- Terns Pharmaceuticals Inc., a global biopharmaceutical company focused on discovering and developing molecularly ...